Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosette Launches First US Generic To AbbVie’s Rectiv

Commercial Shipments To Commence Imminently, With 180 Days Of CGT Exclusivity

Executive Summary

Approval of Cosette’s first US generic to Rectiv came with a six-month exclusivity as the originator drug had “inadequate generic competition,” but the company has 75 days to enter the market.

You may also be interested in...



Deal Watch: Novartis Partners In CNS Gene Therapies A Second Time With Voyager

Plus deals involving AstraZeneca/Allorion, Concentra/Theseus, Janssen/MeiraGTx, Lilly/Fauna and more.

Celltrion’s Subcutaneous Infliximab Lands On Big PBM Formulary List

One down, two more to go. Celltrion seals a formulary deal with one of the top three PBMs in the US for its subcutaneous infliximab product Zymfentra.

Dr Reddy’s Promotes Drug Access With Three Branded Deals In India

With a clear angle of increasing access to medicines in India, Dr Reddy’s signature landed on three branded deals with pharma firms, bringing more vaccines, cardiovascular and resuscitative drugs to the country.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel